A pharmacokinetic profile of desloratadine in healthy adults, including elderly

被引:42
作者
Affrime, M
Gupta, S
Banfield, C
Cohen, A
机构
[1] Schering Plough Res Inst, Kenilworth, NJ USA
[2] Peninsular Testing Corp, Miami, FL USA
关键词
D O I
10.2165/00003088-200241001-00003
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Objective: To characterise the pharmacokinetic profile of desloratadine and its main metabolite, 3-hydroxy (3-OH) desloratadine, in a patient population representative of the population studied in the desloratadine clinical efficacy and safety studies, including the elderly. Design: A multicentre, multidose, open-label pharmacokinetic trial. Participants: 113 healthy adult volunteers (57 men, 56 women; 95 White, 18 Black) were enrolled, and 112 completed the study. Interventions: A 5mg oral dose of desloratadine once daily for 10 days. Main outcome measures: C-max, t(max), t(1/2) and AUC(24h). Results: Steady-state plasma concentrations were attained by day 7. Peak plasma concentrations (Cmax) of desloratadine (mean 3.98 mug/L) and 3-OH desloratadine (mean 1.99 mug/L) were reached at a mean of 3.17 and 4.76 hours (tmax), respectively, after administration. The area under the plasma concentration-time curve from 0 to 24 hours (AUC(24h)) was 56.9 mug/L . h for desloratadine and 32.3 mug/L . h for 3-OH desloratadine. The mean half-lives (t1/2) of desloratadine and 3-OH desloratadine were 26.8 and 36 hours, respectively. There were no clinically relevant differences in the calculated pharmacokinetic parameters of desloratadine when participants were stratified into 3 age,groups (19 to 45, 46 to 64 and 65 to 70 years). Treatment-emergent adverse events occurred in 31 of the 113 participants (3 of the 17 aged greater than or equal to65 years reported adverse events). All adverse events were mild to moderate in severity, and none resulted in discontinuation of treatment. There were no consistent clinically relevant changes in blood pressure, pulse, oral body temperature or electrocardiogram evaluations and no reports of syncope or sedation. Conclusion: Daily administration of desloratadine 5mg is well tolerated. The 27-hour half-life of desloratadine permits once daily administration. No dosage adjustment of desloratadine is required in the elderly.
引用
收藏
页码:13 / 19
页数:7
相关论文
共 10 条
[1]   Effect of race and sex on single and multiple dose pharmacokinetics of desloratadine [J].
Affrime, M ;
Banfield, C ;
Gupta, S ;
Cohen, A ;
Boutros, T ;
Thonoor, M ;
Cayen, M .
CLINICAL PHARMACOKINETICS, 2002, 41 (Suppl 1) :21-28
[2]   Desloratadine has no clinically relevant electrocardiographic or pharmacodynamic interactions with ketoconazole [J].
Banfield, C ;
Herron, J ;
Keung, A ;
Padhi, D ;
Affrime, M .
CLINICAL PHARMACOKINETICS, 2002, 41 (Suppl 1) :37-44
[3]   Lack of clinically relevant interaction between desloratadine and erythromycin [J].
Banfield, C ;
Hunt, T ;
Reyderman, L ;
Statkevich, P ;
Padhi, D ;
Affrime, M .
CLINICAL PHARMACOKINETICS, 2002, 41 (Suppl 1) :29-35
[4]   Cardiovascular safety of second-generation antihistamines [J].
Barbey, JT ;
Anderson, M ;
Ciprandi, G ;
Frew, AJ ;
Morad, M ;
Priori, SG ;
Ongini, E ;
Affrime, MB .
AMERICAN JOURNAL OF RHINOLOGY, 1999, 13 (03) :235-243
[5]   Diagnosis and Management of Rhinitis: Complete guidelines of the Joint Task Force on Practice Parameters in Allergy, Asthma and Immunology [J].
Dykewicz, MS ;
Fineman, S ;
Skoner, DP ;
Nicklas, R ;
Lee, R ;
Blessing-Moore, J ;
Li, JT ;
Bernstein, IL ;
Berger, W ;
Spector, S ;
Schuller, D .
ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY, 1998, 81 (05) :478-518
[6]  
Gibaldi M. P., 1982, PHARMACOKINETICS
[7]   Sedation with "non-sedating'' antihistamines: four prescription-event monitoring studies in general practice [J].
Mann, RD ;
Pearce, GL ;
Dunn, N ;
Shakir, S .
BRITISH MEDICAL JOURNAL, 2000, 320 (7243) :1184-1186
[8]  
MARINO M, 2000, ALLERGY S, V55, P279
[9]   Efficacy and tolerability of once-daily 5mg desloratadine, an H1-receptor antagonist, in patients with seasonal allergic rhinitis -: Assessment during the spring and fall allergy seasons [J].
Meltzer, EO ;
Prenner, BM ;
Nayak, A .
CLINICAL DRUG INVESTIGATION, 2001, 21 (01) :25-32
[10]  
RAMAEKERS JG, 1992, EUR J CLIN PHARMACOL, V42, P363